Star Combo Pharma Ltd. (AU:S66)
ASX:S66
Want to see AU:S66 full AI Analyst Report?
S66 Stock Chart & Stats
AU$0.25
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.25
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.11 - AU$0.28
Previous CloseN/A
Volume100.00K
Average Volume (3M)6.77K
Market Cap
AU$27.68M
Enterprise ValueAU$31.89M
Total Cash (Recent Filing)AU$18.18M
Total Debt (Recent Filing)AU$8.29M
Price to Earnings (P/E)21.2
Beta-0.54
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.54%
Share Statistics
EPS (TTM)0.03
Shares Outstanding135,002,980
10 Day Avg. Volume4,300
30 Day Avg. Volume6,768
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.63
Price to Sales (P/S)0.86
P/FCF Ratio2.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Profitability ReboundAn 18.9% net margin in 2025 represents a material improvement in profitability, indicating successful pricing, cost control or product-mix improvements. Sustained higher margins bolster cash generation and return on capital, providing a durable buffer for reinvestment or shareholder returns if maintained.
Conservative LeverageVery low debt-to-equity (~0.10) gives the company strong balance-sheet flexibility and lower financial risk. This conservative capital structure supports investment in growth, withstands demand shocks, and reduces interest expense sensitivity—advantages that persist across economic cycles.
Strong Cash GenerationRobust operating and free cash flow in 2025 with near 1:1 conversion to net income indicates high earnings quality. Durable cash generation supports capex, dividends, or debt reduction and enhances strategic optionality, improving resilience compared with companies that report accounting profits without cash backing.
Bears Say
Revenue DeclineTop-line fell ~6.3% in 2025 and longer-term revenue growth metrics are weak, implying the recent profit recovery is more margin-driven than volume-driven. Persistent revenue weakness limits scalability, increases reliance on margin improvements, and raises the risk that earnings gains may not be durable.
Historic Earnings And Cash VolatilityThe company has a multi-year history of profit and cash swings, including losses and negative cash flow years. That pattern elevates execution and forecasting risk: a single strong cash year improves the outlook but does not yet prove sustainability across market cycles or against operational setbacks.
Small Scale / Operational ConcentrationA workforce of roughly 30 indicates a small organizational scale relative to larger peers. Limited headcount can constrain R&D, production flexibility and commercial reach, concentrate key-person risk, and slow the ability to scale distribution or enter new markets—structural limits on long-term growth.
Star Combo Pharma Ltd. News
S66 FAQ
What was Star Combo Pharma Ltd.’s price range in the past 12 months?
Star Combo Pharma Ltd. lowest share price was AU$0.11 and its highest was AU$0.28 in the past 12 months.
What is Star Combo Pharma Ltd.’s market cap?
Star Combo Pharma Ltd.’s market cap is AU$27.68M.
When is Star Combo Pharma Ltd.’s upcoming earnings report date?
Star Combo Pharma Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 106 days.
How were Star Combo Pharma Ltd.’s earnings last quarter?
Star Combo Pharma Ltd. released its earnings results on Feb 25, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.
Is Star Combo Pharma Ltd. overvalued?
According to Wall Street analysts Star Combo Pharma Ltd.’s price is currently Overvalued.
Does Star Combo Pharma Ltd. pay dividends?
Star Combo Pharma Ltd. pays a Notavailable dividend of AU$0.004 which represents an annual dividend yield of 1.54%. See more information on Star Combo Pharma Ltd. dividends here
What is Star Combo Pharma Ltd.’s EPS estimate?
Star Combo Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Star Combo Pharma Ltd. have?
Star Combo Pharma Ltd. has 135,002,980 shares outstanding.
What happened to Star Combo Pharma Ltd.’s price movement after its last earnings report?
Star Combo Pharma Ltd. reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of Star Combo Pharma Ltd.?
Currently, no hedge funds are holding shares in AU:S66
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Star Combo Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.20%
12-Months-Change
Fundamentals
Return on Equity
14.06%
Trailing 12-Months
Asset Growth
8.47%
Trailing 12-Months
Company Description
Star Combo Pharma Ltd.
Star Combo Pharma Limited engages in the manufacturing and distribution of health food products and nutritional supplements in Australia and China. The company operates in two segments, Star Combo and Austoyou Retail. It develops, manufactures, markets, and sells natural health supplements and skin care products. The company provides its products through e-commerce platform to Chinese health product consumers; and two retail stores in Sydney. Star Combo Pharma Limited was founded in 2004 and is based in Smithfield, Australia.
Technical Analysis
Zoono Group Limited
―
Nanollose Ltd.
―
Skin Elements Limited
―
Lumos Diagnostics Holdings Ltd.
―
―